Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Interventions
DRUG

Rituximab

Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase

Trial Locations (1)

Unknown

Shang-Ju Wu, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER